Product Description
Cefuroxime is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/cefuroxime-oral-route/side-effects/drg-20073295?p=1)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Otitis | Otitis Media | Pharyngitis | Tonsillitis | Gonorrhea | Impetigo | Lyme Disease | Urinary Tract Infections | Bronchitis | Bronchitis, Chronic | Maxillary Sinusitis | Sinusitis
Known Adverse Events: Diaper Rash | Lyme Disease | Vaginitis | Diarrhea
Company: Rizhongtian Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, Denmark, France, Italy, Netherlands, Spain, Unknown Location
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Other|Retinitis Pigmentosa
Phase 1: Arthritis, Infectious|Bacteriuria|Bronchiectasis|Bronchitis, Chronic|Cellulitis|Cystitis|Erysipelas|Gonorrhea|Lung Abscess|Meningitis, Bacterial|Osteoarthritis|Osteomyelitis|Pelvic Infection|Peritonitis|Pharyngitis|Pneumonia, Bacterial|Pyelonephritis|Respiratory Tract Infections|Sepsis|Sinusitis|Soft Tissue Infections|Tonsillitis|Urinary Tract Infections|Wound Infection
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MGT-RPGR-022 | P3 |
Unknown Status |
Retinitis Pigmentosa |
2029-12-19 |
|
| CTR20130509 | P1 |
Recruiting |
Arthritis, Infectious|Pharyngitis|Tonsillitis|Soft Tissue Infections|Pyelonephritis|Respiratory Tract Infections|Pelvic Infection|Sinusitis|Sepsis|Osteoarthritis|Urinary Tract Infections|Wound Infection|Erysipelas|Gonorrhea|Cystitis|Peritonitis|Osteomyelitis|Pneumonia, Bacterial|Meningitis, Bacterial|Bacteriuria|Cellulitis|Bronchiectasis|Lung Abscess|Bronchitis, Chronic |
None |
|
| CTR20150519 | P3 |
Recruiting |
Other |
None |